{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027812","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.287841+00:00","generated_at":"2026-06-22T12:46:04.841731+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vanda Q3 2022 revenue $65.3M (-7% YoY); net income $3.3M; narrows full-year guidance","bullets":["Q3 total revenues $65.3M, down 7% from $70.1M; HETLIOZ sales $41.3M (-9%), Fanapt $24.0M (-2%).","Net income $3.3M ($0.06 diluted EPS) vs $7.8M ($0.14) a year ago; first nine months net loss $0.6M.","Full-year 2022 revenue guidance narrowed to $240-270M (from $240-280M); year-end cash forecast >$450M.","Cash, cash equivalents and marketable securities $454.8M as of Sept 30, up $48.8M YoY.","Pipeline: sNDA for HETLIOZ in insomnia expected by end-2022; NDA for tradipitant in gastroparesis expected H1 2023; Fanapt bipolar Phase III fully enrolled, results by end-2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027812","json":"https://secwatch.observer/filing/0001628280-22-027812.json","markdown":"https://secwatch.observer/filing/0001628280-22-027812.md","text":"https://secwatch.observer/filing/0001628280-22-027812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/0001628280-22-027812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/vnda-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:46:04.841731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c58c5a81074b52dc935e8622735d592ab2208cfa","claim":"Vanda Pharmaceuticals Inc. reported third quarter ended September 30, 2022 results: net income $3.3 million, EPS $0.06.","evidence_excerpt":"Net income was $3.3 million in the third quarter of 2022 compared to net income of $7.8 million in the third quarter of 2021. Diluted net income per share was $0.06 in the third quarter of 2022 compared to diluted net income per share of $0.14 in the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/0001628280-22-027812-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$3.3 million"},{"label":"EPS","value":"$0.06"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ca21161888996aa41f309df2c1841ec5fa23ea10","claim":"Vanda Pharmaceuticals Inc. reported full year 2022 results: revenue $240 to $270 million. Guidance lowered.","evidence_excerpt":"Vanda is updating its 2022 financial guidance and expects to achieve the following financial objectives in 2022 : Full Year 2022 Financial Objectives Revised Full Year 2022 Guidance Prior Full Year 2022 Guidance Total revenues $240 to $270 million $240 to $280 million HETLIOZ ® net product sales $150 to $170 million $150 to $180 million Fanapt ® net product sales $90 to $100 million $90 to $100 million Year-end 2022 Cash Greater than $450 million Greater than $440 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/0001628280-22-027812-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$240 to $270 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}